Hansa Biopharma, announced that Matthew Shaulis will join the company effective 16 March as Chief Commercial Officer and President of the U.S. affiliate, Hansa Biopharma Inc. He will report to President and CEO Søren Tulstrup and join the Executive Committee.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
49.64 SEK | +12.82% | +21.07% | +89.47% |
05-31 | Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial | MT |
05-31 | Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+89.47% | 298M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- HNSA Stock
- News Hansa Biopharma AB
- Hansa Biopharma AB Appoints Matthew Shaulis as Chief Commercial Officer and US President of Hansa Biopharma